Bristol Myers Squibb plans a 600,000-square-foot Houston campus that will manufacture small molecules, biologics and antibody-drug conjugates
Bristol Myers Squibb (BMS) is investing approximately $2.3 billion in a new manufacturing campus in Houston, Texas.
The 600,000-square-foot facility will be located at Generation Park in northeast Houston. It will support the manufacturing of small-molecule medicines, biologics and antibody-drug conjugates (ADCs), including drug product and finished goods manufacturing from late-stage development through launch.
BMS plans to use a modular design that will allow manufacturing capacity to be added or reconfigured as its pipeline changes.
The project is expected to create nearly 500 jobs across manufacturing, engineering, maintenance, quality and other operations. BMS also expects approximately 2,000 construction and related jobs between 2027 and 2030 while the campus is being built.
Get industry leading pharma and biotech news, events and expert insights delivered to your inbox.
The Houston project is part of BMS’ plans to invest $40 billion in the US over five years across manufacturing, research and development and technology. The company announced its plans in May 2025 while drugmakers were preparing for the possibility of tariffs on pharmaceutical imports.
BMS later reached an agreement with the US government in December 2025 that provides the company with three years of tariff relief. The agreement also includes commitments related to drug pricing, access and supply, while BMS said it would continue expanding domestic production as part of its $40 billion US investment plan. Specific terms of the agreement remain confidential.
Houston has already attracted another multibillion-dollar pharmaceutical manufacturing project. In September 2025, Eli Lilly announced plans to invest more than $6.5 billion in an approximately 1-million-square-foot active pharmaceutical ingredient manufacturing facility at Generation Park. The project is expected to create more than 600 jobs.
In the Houston area, more and more pharma manufacturing investments are taking root. In March, the CDMO LGM Pharma announced an additional $9 million investment across its Texas and Colorado sites. Of that amount, $4 million is going toward its Rosenberg, Texas, facility, where the company is expanding commercial-scale manufacturing and R&D capabilities for several finished dosage forms. LGM Pharma had previously announced a $6 million expansion at the Rosenberg site.
BMS will also receive a $4.89 million Texas Enterprise Fund grant, while the Houston project qualifies for additional state incentives.
Large drugmakers have continued expanding their US footprint. According to Reuters, companies including Eli Lilly, Pfizer, Johnson & Johnson, Roche, AstraZeneca and Novartis have announced investments totaling more than $500 billion across US manufacturing, research and supply-chain infrastructure.
If you want your company to be featured on Xtalks.com, please email [email protected].
Join or login to leave a comment
JOIN LOGIN